Epithelioid sarcoma expresses epidermal growth factor receptor but gene amplification and kinase domain mutations are rare
- 1 April 2010
- journal article
- Published by Elsevier in Laboratory Investigation
- Vol. 23 (4) , 574-580
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Prognostic Factors for Survival in Patients with Epithelioid Sarcoma: 441 Cases from the SEER DatabaseClinical Orthopaedics and Related Research, 2009
- Update in Antiepidermal Growth Factor Receptor Therapy in the Management of Metastatic Colorectal CancerJournal of Oncology, 2009
- Delta-Crystallin Enhancer Binding Factor 1 Controls the Epithelial to Mesenchymal Transition Phenotype and Resistance to the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Human Head and Neck Squamous Cell Carcinoma LinesClinical Cancer Research, 2009
- Epithelioid Sarcoma: A Case Report with Ultrastructural Confirmation of Myofibroblastic Differentiation Based on Fibronexus JunctionsUltrastructural Pathology, 2009
- Epidermal Growth Factor Receptor Expression and Mutational Analysis in Synovial Sarcomas and Malignant Peripheral Nerve Sheath TumorsThe Oncologist, 2008
- Epithelioid Sarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single InstitutionAnnals of Surgical Oncology, 2007
- Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancerAnnals of Oncology, 2006
- Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene MutationsJournal of Clinical Oncology, 2006
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004